Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5353436 | 0.98 | KDM4E (0.70) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL23112136 | 0.89 | KDM4E (0.58) | KDM4EATMTAAR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL5362235 | 0.87 | KDM4E (0.56) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL943423 | 0.86 | KDM4E (0.53) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL8145667 | 0.85 | ATM (0.52) | KDM4EATMTAAR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL3646139 | 0.85 | KDM4E (0.52) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL988997 | 0.85 | KDM4E (0.72) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL210639 | 0.84 | ATM (1.00) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL29351641 | 0.84 | ATM (1.00) | KDM4EATMTAAR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL1437290 | 0.83 | KDM4E (0.70) | KDM4EATMTAAR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | claimed |
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| EP-4139294-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-115667243-B | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12098148-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2008019690-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2008-02-21 | — | — | WO | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050065171-A1 | Substituted purine derivatives | ARIAD PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005009348-A2 | SUBSTITUTED PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | KDM4E 4678/4885ATM 2999/4885TAAR1 1200/4885 |
| US-20050065171-A1 | Substituted purine derivatives | ADORA2A, PNP, HPRT1 | KDM4E 2177/4885ATM 3088/4885TAAR1 617/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | KDM4E 4007/4885ATM 3483/4885TAAR1 1406/4885 |
| US-12098148-B2 | Therapeutic compounds | NFE2L2, KEAP1, NQO1 | KDM4E 3963/4885ATM 2297/4885TAAR1 3678/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | KDM4E 4646/4885ATM 1037/4885TAAR1 1932/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | KDM4E 3210/4885ATM 1418/4885TAAR1 1584/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | KDM4E 3963/4885ATM 2297/4885TAAR1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.